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Abstract
AIM: To determine the short-term cost-utility of mo-
lecular adsorbent recirculating system (MARS) treat-
ment in acute liver failure (ALF).
METHODS: A controlled retrospective study was con-
ducted with 90 ALF patients treated with MARS from 
2001 to 2005. Comparisons were made with a historical 
control group of 17 ALF patients treated from 2000 to 
2001 in the same intensive care unit (ICU) specializing 
in liver diseases. The 3-year outcomes and number 
of liver transplantations were recorded. All direct liver 
disease-related medical expenses from 6 mo before to 
3 years after ICU treatment were determined for 31 
MARS patients and 16 control patients. The health-relat-
ed quality of life (HRQoL) before MARS treatment was 
estimated by a panel of ICU doctors and after MARS 
using a mailed 15D (15-dimensional generic health-
related quality of life instrument) questionnaire. The 
HRQoL, cost, and survival data were combined and the 
incremental cost/quality-adjusted life years (QALYs) was 
calculated. 
RESULTS: In surviving ALF patients, the health-related 
quality of life after treatmeant was generally high and 
comparable to the age- and gender-matched general 
Finnish population. Compared to the controls, the aver-
age cost per QALY was considerably lower in the MARS 
group (64 732€ vs  133 858€) within a timeframe of 3.5 
years. The incremental cost of standard medical treat-
ment alone compared to MARS was 10 928€, and the 
incremental number of QALYs gained by MARS was 0.66. 
CONCLUSION: MARS treatment combined with stan-
dard medical treatment for ALF in an ICU setting is more 
cost-effective than standard medical treatment alone. 
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Since its introduction in 1993[1,2], the molecular adsorbent 
recirculating system (MARS) has been used in the treat-
ment of  both acute liver failure (ALF) and acute-on-
chronic liver failure (AOCLF). The MARS device is an ex-
tracorporeal albumin dialysis apparatus that removes both 
albumin-bound and water-soluble toxins from the patient’s 
blood, enabling native liver regeneration and allowing time 
to locate a suitable organ for liver transplantation (Ltx)[3-5]. 
Numerous studies have documented the favorable 
effects of  MARS treatment on clinical and laboratory pa-
rameters[4,6-9] and survival[10-13]. However, only three small 
non-randomized studies[14-16] have focused on the cost-
utility of  MARS treatment in AOCLF and the health-
related quality of  life (HRQoL) of  MARS-treated AOCLF 
patients. Currently, there are no studies on the HRQoL or 
cost-utility of  MARS treatment in ALF patients. 
In assessing therapy utility, the subjective feelings of  
the patient should be taken into account in addition to 
health benefits (e.g. survival) and cost. To ensure that lim-
ited resources are utilized in an ethical manner, the impact 
of  a given treatment on the future HRQoL of  the patient 
must be considered[17]. The effectiveness of  a given treat-
ment should be assessed by considering the treatment’s 
impact on both the length and quality of  life, which can 
be combined into the measure quality-adjusted life years 
(QALYs). In the cost-utility analysis, the QALYs gained 
by a given treatment are used as the measuring units of  
efficacy. Thus, the QALYs and cost/QALY-ratios can 
be used to compare the different treatments in terms of  
length of  life and quality of  life. Currently, there is no 
consensus as to how much a QALY gained can cost, but a 
50 000€ threshold has been suggested[17].
The aim of  this study was to determine the short-term 
(3.5 years) cost-utility of  MARS treatment in ALF patients. 
MATERIALS AND METHODS
Patients 
This study included 90 ALF patients treated with MARS 
from May 2001 to October 2005 and a historical control 
group of  17 consecutive ALF patients treated from March 
2000 to April 2001. ALF was defined as a rapid deterio-
ration of  hepatic synthetic function with or without en-
cephalopathy and no previous history of  liver disease[18]. 
All patients were treated in the same intensive care 
unit (ICU) specializing in liver disease at the Helsinki Uni-
versity Hospital and according to the same main principles 
of  standard medical therapy (SMT). The SMT in our ICU 
and the operational principles of  the MARS device were 
reported previously[3-5]. Our liver ICU is the only Ltx cen-
ter in Finland, and all critical ALF patients are referred to 
our unit for treatment and transplantation evaluation. The 
indications for MARS treatment and the treatment proto-
cols are summarized in Table 1. The 3-year survival and 
the need for Ltx were determined in all patients. 
Economic evaluation
In the cost-utility analysis, effectiveness was measured as 
QALYs gained. The costs and outcomes of  MARS treat-
ment were compared with those of  SMT in the control 
group over a 3-year time horizon from the perspective of  
the health care provider. For this comparison, a determin-
istic decision model was developed using TreeAge Pro 
HealthCare software (TreeAge, Williamstown, MA, USA). 
The model was used to combine the data on costs and 
effectiveness and to incorporate data variability and uncer-
tainty into the analysis (Figure 1). The pathways presented 
in Figure 1 are mutually exclusive sequences of  events, 
and the expected values are based on the pathway values 
weighted by the pathway probabilities. The probabilities 
show the proportion of  the patient cohort that is expected 
to experience the event at any particular point in the tree. 
The incremental cost-effectiveness ratio (ICER) was 
determined by dividing the difference in costs by the dif-
ference in QALYs. Both costs and QALYs were discount-
ed 5% as currently recommended in the Finnish guidelines 
for pharmacoeconomic evaluation. The base-case analysis 
estimated the cost-effectiveness based on the mean values 
from the data in the simplified model structure. The effect 
of  model input parameter uncertainty on the results was 
tested in a one-way and probabilistic sensitivity analysis. 
Direct costs
From the year 2000 onwards, the Helsinki University 
Central Hospital district began to use the clinical patient-
administration database Ecomed® for registering all treat-
ment costs. In this study all direct medical costs were 
obtained from the Ecomed®-database (Datawell Ltd., 
Espoo, Finland). The total costs included all relevant liver 
disease-related expenses incurred at the Helsinki Univer-
sity Hospital. All costs incurred between 6 mo before the 
first MARS treatment (or liver ICU admission in the con-
trol group) and 3 years after the treatment were included. 
Complete cost data were available only for those patients 
who were living (31 MARS and 16 control patients) and 
received all hospital care in the catchment area of  the Hel-
sinki and Uusimaa Hospital District. Therefore, patients 
referred from outside the catchment were excluded from 
the cost analysis. Direct non-medical costs (transportation, 
domestic help, productivity costs due to absences from 
work, etc.) were not included. The mean total cost within 
the specified time period was used in the base-case analy-
sis. All costs in Euros were inflated to the 2006 price level. 
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HRQoL
The HRQoL was measured by the 15D (15-dimensional 
generic health-related quality of  life instrument)[19-21], 
which is a generic, self-administered questionnaire for 
adults using criteria related to 15 dimensions: moving, 
seeing, hearing, breathing, sleeping, eating, speech, elimi-
nating, usual activities, mental function, discomfort and 
symptoms, depression, distress, vitality, and sexual activ-
ity. For each dimension, the patient chooses one of  five 
levels that best describes his/her current state of  health. 
A set of  utility weights is used to generate a single index 
number, the 15D score, which ranges from 0 to 1 (1 = full 
health, 0 = dead)[22]. For most of  the important proper-
ties (i.e. reliability, content validity, discriminatory power, 
and responsiveness to change), the 15D is at least equal 
to other similar HRQoL instruments, such as the EQ-5D, 
SF-6D, HUI3, and AqoL[19-21,23-25]. 
Most ALF patients admitted to our liver ICU are seri-
ously ill and encephalopathic, if  not unconscious, and 
thus unable to fill out the HRQoL questionnaires. There-
fore, we used expert opinion to assess the pre-treatment 
HRQoL. Three ICU doctors separately and retrospec-
tively estimated the HRQoL of  30 ALF patients using 
the 15D instrument and the patients’ clinical documents. 
All patients were divided into five groups according to 
their pre-treatment encephalopathy grade, which was 
represented as a number from 0 to 4. The HRQoL was 
assessed in all patients who were conscious and not in-
tubated. The HRQoL was evaluated for six randomly se-
lected non-intubated patients from each encephalopathy 
grade 0-3, and their average 15D score was assumed to 
represent the approximate HRQoL of  the entire group 
(Table 2). Unconscious and intubated patients, which 
included some encephalopathy grade 3 patients and all 
encephalopathy grade 4 patients, received a 15D score of  
0.0162[22]. 
In July 2007, the 15D questionnaire was sent to the 
68 MARS-treated ALF patients who were still alive (one 
patient was not found). Two reminder letters were sent to 
those who did not return the first questionnaire. In total, 
79% (54/68) completed the post-treatment 15D ques-
tionnaire; 37% of  these patients (20/54) had undergone 
Ltx. At the time of  the survey, the time elapsed after the 
first MARS treatment varied among individual patients 
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Liver failure
64 414€ 0.00
MARS
Standard medical treatment
Contraindication to liver transplant
0.41
No contraindication to liver transplant (n  = 10)
0.59
Liver transplantation (n  = 8)
0.8
No liver transplantation
0.2
Survive 3y (n  = 2)
Dead (n  = 7)
Survive 3y (n  = 5)
Dead (n  = 3)
0.625
0.375
Liver transplantation (n  = 26)
0.36
No liver transplantation  (n  = 46)
0.64
Survive 3y (n  = 24)
Dead (n  = 2)
0.92
0.08
Survive 3y (n  = 39)
Dead (n  = 7)
0.85
0.15
Survive 3y (n  = 7)
Dead (n  = 11)
0.39
0.61
No contraindication to liver transplant (n  = 72)
0.8
Contraindication to liver transplant (n  = 18)
0.2
Costs QALYs
52 492€ 1.85
89 471€ 0.01
41 957€ 2.00
171 157€ 0.11
210 012€ 1.61
45 089€ 0.00
77 162€ 1.69
180 285€ 0.01
170 578€ 1.79
Figure 1  A deterministic decision model. In both treatment arms, the patient cohort was divided based on contraindication vs no contraindication to liver transplantation 
(Ltx) and then on the basis of Ltx vs no-Ltx. The “survive 3y” branches include all patients who survived at least three years after the first treatment, and the “death” 
branches include all patients who died within those three years. The pathway probabilities i.e. the proportion of the cohort that is expected to experience the event, are 
shown under each branch and were calculated based on real patient data. MARS: Molecular adsorbent recirculating system; QALY: Quality-adjusted life year.
Table 1  MARS treatment protocols for acute liver failure in Finland
Etiology MARS treatment initiation criteria Treatment protocol
Acute liver 
failure
Rapid deterioration of hepatic synthetic function and clinical condition despite conservative 
standard medical therapy
22-h sessions daily until:
(1) Native liver recovers
And one of the following criteria: (2) Suitable transplant organ is found
(1) Ingestion of a lethal dose of a known hepatotoxin (e.g. Amanita, paracetamol) (3) Irreversible multi-organ damage occurs
(2) The patient fulfills the criteria for highly urgent liver transplantation
MARS: Molecular adsorbent recirculating system.
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(median 49 mo, range 22-72 mo). Thus, a 15D score 3 
years after the first MARS treatment was individually es-
timated for each patient using linear regression analysis 
with the patient’s age, time since MARS treatment, and 
the etiology of  liver failure as explanatory variables. 
The mean 15D scores and resulting QALYs were cal-
culated separately for each pathway in the decision tree 
(Figure 1). For patients who died within the time hori-
zon, QALYs were calculated based on survival, assuming 
the 15D score declined linearly from the baseline value 
to zero at the time of  death. 
Sensitivity analysis
The effect that model parameter uncertainty had on the 
results was examined first in a one-way analysis and fur-
ther in a probabilistic sensitivity analysis. In the one-way 
sensitivity analysis, the discount rate, the mean cost and 
QALYs of  both the MARS and control groups, the prob-
ability of  Ltx, and survival rates varied. For the probabi-
listic sensitivity analysis, probability distributions for tree 
probabilities, cost, and utility input parameters were esti-
mated. The results of  the probabilistic sensitivity analysis 
are presented as a cost-effectiveness acceptability curve 
(Figure 2). Probability and utility values are represented by 
beta distributions (limiting values between 0 and 1 for util-
ity values), the parameters of  which were estimated from 
the patient data. For cost estimates, a gamma distribution 
was determined. Because the actual patient level cost data 
were limited, regression analysis was used to estimate 
costs for all patients. Sex, Ltx and its contraindication, and 
the number of  MARS treatments received were used as 
explanatory variables in the regression analysis.
Statistical analysis
All data were analyzed using SPSS for Windows ver-
sion 15.0 (SPSS, Inc., Chicago, IL, USA). The Wilcoxon 
signed-rank test, the Mann-Whitney U-test, Pearson’s χ2, 
and Fisher’s exact tests were used when appropriate. P 
≤ 0.05 was considered significant, and a ≥ 0.03 (absolute 
value) difference in the HRQoL scores was considered 
clinically important[26]. 
RESULTS
Characteristics of the study population
The demographic and clinical characteristics of  the 
MARS-treated and control ALF patients did not differ 
significantly, with the exception of  a need for vasoactive 
infusion (Table 3). The grade of  encephalopathy before 
treatment was also comparable between the two groups. 
The etiological distribution of  ALF patients differed be-
tween the groups (P = 0.002). Control patients had mostly 
ALF of  unknown etiology (65%), whereas the majority 
of  MARS-treated patients (57%) had ALF due to known 
toxicity (e.g. paracetamol or other drugs). 
Outcome and 3-year survival
The percentage of  transplanted patients was lower (29% 
vs 47%, P = 0.14), and the percentage of  patients who sur-
vived 3 years after treatment was higher (78% vs 41%, P = 
0.002) in the MARS-treated group compared to controls. 
2230 May 14, 2010|Volume 16|Issue 18|WJG|www.wjgnet.com
Table 2  Mean pre-treatment 15D scores in different 
encephalopathy grade groups (mean ± SD)
Pre-treatment encephalopathy grade 15D score
0 0.532 ± 0.151
1 0.461 ± 0.188
2 0.403 ± 0.177
3 0.079 ± 0.077
4 0.016
The average age-matched 15D score of the Finnish population is 0.92, and 
the standardized 15D score for unconscious/intubated patients is 0.016[22].
Table 3  Baseline data for the MARS and control groups
MARS 
group
Historical 
control group
P  
value
Pre-treatment demographic & clinical data
   Number of patients 90 17
   Age (yr)   45 (14-81) 42 (21-72) 0.714
   Sex (male)   37 (41%) 7 (41%) 0.996
   Body mass index (kg/m2)   26 (17-40) 26 (21-37) 0.372
   MARS sessions/patient     2 (1-9) 0
   Mechanically ventilated   30 (33%) 6 (35%) 0.875
   Vasoactive infusion used   27 (30%) 9 (56%) 0.041
   Renal insufficiency   29 (32%) 7 (41%) 0.474
   MELD-score   31 (5-50) 30 (19-51) 0.225
   Mean encephalopathy grade 1.7 ± 1.6 2.1 ± 1.7 0.335
   Contra-indication to Ltx prior to 
   treatment
  11 (12%) 4 (24%) 0.253
   Became untransplantable during 
   treatment
    7 (8%) 3 (18%) 0.195
   Number of transplanted patients   26 (29%) 8 (47%) 0.162
Pre-treatment key laboratory values
   Platelets (× 109/L) 138 (11-410)   142 (51-448) 0.919
   NH4 ion (µmol/L)   68 (8-512)     90 (14-241) 0.559
   Bilirubin (µmol/L) 215 (4-761)   381 (38-880) 0.057
   Creatinine (µmol/L)   75 (35-1318)     78 (38-275) 0.946
   FV (%)   32 (5-142)     38 (7-71) 0.865
All values are expressed as median (range) or as number of patients 
(%). Hepatic encephalopathy grade is presented as mean ± SD. MELD 
score: Mean end-stage liver disease score; Ltx: Liver transplantation; FV: 
Coagulation factor Ⅴ. 
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
Pr
ob
ab
ili
ty
 o
f 
be
in
g 
co
st
-e
ff
ec
tiv
e
0     15    30    45    60    75    90   105  120   135  150
Willingness-to-pay per QALY (× 103€)
MARS treatment
Control group
Figure 2  The cost-effectiveness acceptability curve for MARS vs standard 
medical therapy in the historical control group in acute liver failure.
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A similar survival benefit favoring MARS treatment com-
pared to controls was noted in both transplanted (92% vs 
63%, P = 0.072) and non-transplanted patients (72% vs 
22%, P = 0.006).
Costs
The total mean direct medical costs related to liver disease 
were 79 745€ for the MARS group and 105 820€ for the 
controls (Table 4). The total mean direct medical costs 
for transplanted and non-transplanted MARS and control 
patients are shown in Figure 3 and the expected costs 
weighted by the pathway probabilities are shown in Table 5.
In all patient groups, most of  the costs were incurred 
within a year of  the first MARS or standard medical 
treatment. The costs during the second and third years 
were negligible. In all groups, the highest costs were ob-
served in transplanted patients.
HRQoL and QALYs
The pre- and post-treatment 15D scores are shown in 
Figure 4 and Table 4. The estimated HRQoL for all pa-
tients prior to treatment was very low compared to an 
age-standardized reference population in Finland (0.30 vs 
0.92)[27]. The highest post-treatment 15D scores were ob-
served in MARS-treated patients who did not have a con-
traindication to Ltx and recovered without transplanta-
tion. The same patients also experienced the highest mean 
number of  QALYs (2.00, within the 3-year follow-up). 
The groups with the smallest mean number of  QALYs 
were patients with a contraindication to Ltx and those 
who died within 3 years of  treatment. 
Cost-utility analysis
In the base-case analysis, the MARS group strongly domi-
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Table 4  The survival, cost, and HRQoL data of MARS-treated and control patients
Subgroups according to 
outcome
3-yr survival Cost (€) HRQoL
n % Mean (d) n Mean Min Max n Pre-treatment 
mean
Post-treatment 
mean
MARS 
group
All ALF patients 90 78 31 79 745 11 961 370 573 90 0.30 0.70
   Alive at 3 yr 70 24 78 724 11 961 370 573 70 0.34 0.89
   Dead 20   63   7 83 243 32 496 171 157 20 0.15 0.00
Contraindication to Ltx 18 39
   Alive at 3 yr   7   4 52 492 30 325 112 585   7 0.38 0.85
   Dead 11   14   5 64 414 32 496   95 666 11 0.13 0.00
No contraindication - no Ltx 46 85
   Alive at 3 yr 39 15 41 957 11 961 137 235 39 0.40 0.93
   Dead   7 110   1 89 471   7 0.09 0.00
Transplanted 26 92
   Alive at 3 yr 24   5 210 012 96 984 370 573 24 0.22 0.84
   Dead   2 169   1 171 157   2 0.47 0.00
Control 
group
All ALF patients 17 41 16 105 820 16 862 262 481 17 0.27 0.36
Contraindication to Ltx   0
   Dead   7     9   7 45 089 17 591 105 917   7 0.27 0.00
No contraindication - no Ltx    100
   Alive at 3 yr   2   2 77 162 16 862 137 462   2 0.27 0.85
Transplanted 63
   Alive at 3 yr   5   4 170 578 117 444 262 481   5 0.32 0.87
   Dead   3   28   3 180 285 129 120 250 772   3 0.19 0.00
HRQoL: Health-related quality of life; ALF: Acute liver failure.
Table 5  Base case results for MARS
Cost (€) Incremental cost (€) QALYs Incremental QALYs Cost per QALY (€) Incremental cost per QALY
MARS   93 214 1.44 0.66   64 732 MARS dominates SMT
Control group (SMT only) 104 142 10 928 0.78 133 858
SMT: Standard medical therapy; QALY: Quality-adjusted life year.
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Figure 3  The 3.5-year mean overall direct medical costs per patient in the 
MARS and control groups. ALF: Acute liver failure.
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nated the control group receiving only SMT; MARS treat-
ment was both less costly and more effective than SMT in 
ALF patients (Table 5). Using the 3-year time horizon, the 
expected outcome of  MARS patients was 1.44 QALYs 
and the expected costs were 93 214€. The corresponding 
figures for the controls were 0.78 and 104 142€, respec-
tively. Compared to MARS, the incremental cost of  SMT 
in the control group was 10 928€. The incremental num-
ber of  QALYs gained by MARS was 0.66. 
Sensitivity analysis
MARS remained the dominant strategy throughout most 
of  the one-way sensitivity analyses. Neither increasing 
the proportion of  patients with a contraindication to 
Ltx in the MARS group nor varying the survival rates of  
patients after Ltx or MARS-treated patients with a contra-
indication, mitigated the dominance of  MARS treatment. 
MARS also remained the dominant strategy throughout 
QALY estimate variation in the one-way sensitivity analy-
sis. Using a discount rate of  0%, 3%, or 5% did not elimi-
nate the dominance.
The results were more sensitive to variation in the 
cost estimates. In the one-way sensitivity analysis, in-
creasing the costs for MARS-treated patients who had 
no contraindication and survived three years with Ltx 
removed the dominance of  MARS and resulted in an 
ICER of  63 206€ per QALY gained. 
The proportion of  liver disease with unknown etiol-
ogy was significantly higher in the control group (P = 
0.002), which can lead to a higher probability of  Ltx. 
We varied the probability of  Ltx in the MARS group 
from 0.89 (observed in controls) to 0.36 (observed in 
the MARS-treated group); throughout which, MARS 
remained the more effective alternative. However, when 
the probability of  Ltx in the MARS group was increased 
to 0.42 or higher, the expected cost of  MARS exceeded 
that of  the control group receiving SMT, and its domi-
nance was eliminated. When the probability of  Ltx in 
the MARS group was set to the same level as the control 
group (0.89), the ICER was 98 686€ per QALY gained. 
The cost-effectiveness acceptability curve (Figure 2) of  
MARS vs controls showed the probability that MARS is 
cost-effective given a range of  willingness-to-pay thresh-
olds per QALY gained. If  the decision-maker is willing to 
pay 50 000€ per QALY, the probability of  MARS being 
cost-effective is 78%. Furthermore, the probability of  
MARS being cost-effective is 95% if  the willingness-to-
pay threshold is 200 000€ per QALY. 
DISCUSSION
To our knowledge, there are no previous studies evaluat-
ing the cost-utility of  MARS treatment in ALF patients. 
We found that MARS treatment was both less costly and 
more effective than SMT in ALF. Compared to the con-
trols, the average cost per QALY was significantly lower 
in the MARS group (64 732€ vs 133 858€), mainly due to 
the significantly higher 3-year overall survival rate and 
fewer transplantations in the MARS group. 
The average overall 3.5-year costs associated with the 
treatment of  ALF were substantial with or without MARS 
treatment due to the long ICU stay and, in some cases, 
Ltx costs. The fewer Ltx in the MARS group resulted in 
reduced overall average costs compared to conservative 
treatment. Because the costs associated with the Ltx pro-
cedure are high, any intervention that decreases the num-
ber of  transplantations is bound to have a profound effect 
on the total expense. 
As reported previously[28,29], we found that, even 
though the HRQoL of  surviving transplanted patients 
was generally very good, it was still somewhat lower than 
that of  a person in the age-standardized general popula-
tion (0.84 vs 0.92)[27]. In ALF patients who recovered with-
out Ltx, the HRQoL after treatment was similar to that of  
the age-standardized Finnish reference population (0.93 vs 
0.92)[27].
Only a handful of  HRQoL and cost-effectiveness 
studies have been completed on MARS patients, and 
all have been limited to AOCLF patients treated in the 
same center[14-16]. Until now, MARS-treated ALF patients 
have not been evaluated in terms of  total cost and QA-
LYs, possibly owing to the rarity of  the condition, which 
makes it difficult to enroll enough patients for statistical 
analysis. Furthermore, comparing results from different 
studies can be difficult because transplant organ avail-
ability varies, and centers may have different criteria for 
MARS treatment. In addition, the heterogeneity of  the 
etiology of  ALF in different countries markedly affects 
survival rates and the percentage of  patients who may 
experience native liver recovery[30,31].
The most recent cost-utility evaluation of  MARS treat-
ment included 79 alcohol-related AOCLF patients[14]; their 
3-year survival was 52% with mean direct medical costs 
of  40 032€ and an ICER of  31 448€ per life-year gained. 
However, transplanted patients and those with serious co-
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morbidities were excluded from this analysis, which had 
a huge impact on the total costs. Another study focused 
on the impact of  MARS treatment on the hospitalization 
costs and 1-year survival of  cirrhotic AOCLF patients[32]; 
the in-hospital cost for surviving MARS-treated patients 
was $32 036, $4000 less than in the control group. 
The main limitation of  this study was the nonrandom-
ized design. Also, due to patient incapacitation, the pre-
treatment HRQoL was retrospectively assessed by an ex-
pert panel rather than by the patients themselves. Studies 
have shown that the subjective feelings of  a patient, such 
as pain or HRQoL, are usually misjudged or underestimat-
ed by the attending doctors, other treatment staff, or even 
close relatives[33,34]. Another factor affecting the positive 
outcomes of  MARS-treated ALF patients in this study 
was the uneven distribution of  liver failure etiologies be-
tween treatment groups. The prognosis and need for Ltx 
is strongly related to the underlying cause of  ALF[30]; the 
MARS treatment group was at an advantage in that it in-
cluded many patients with a good prognosis compared to 
controls. This predisposition must be taken into account 
when interpreting the results of  this study. The sensitivity 
analysis was used to estimate the effect of  this bias, and 
it seems that even if  both the MARS and control groups 
had a similar distribution of  etiologies, MARS treatment 
would remain the more effective strategy, although more 
expensive in terms of  total cost. 
One must bear in mind that this study dealt with a 
3.5-year time window, thus severely underestimating the 
QALYs to be gained over the remaining lifetime. Alter-
natively, we could have extrapolated the expected lifetime 
costs and outcomes; however, this would have necessitat-
ed further assumptions and resulted in greater uncertainty. 
In conclusion, cost-utility analysis found that MARS 
treatment plus SMT is both less costly and more effective 
than SMT alone in ALF patients. Although some uncer-
tainty exists in the model input parameters, probabilistic 
sensitivity analysis showed that the probability of  MARS 
being cost-effective is higher than that of  SMT alone. 
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